Natural Product Libraries in Drug Discovery
Natural products exhibit bioactive diversity and translational ability, positioning them as drivers of drug discovery.
Natural product libraries play a foundational role in modern drug discovery, enabling the identification of bioactive compounds across therapeutic areas.
These libraries are large, systematically organized collections of molecules derived from living organisms, which can be used in high-throughput screening (HTS) to identify biologically active compounds and new drug candidates.
Despite predating synthetic and combinatorial chemistry approaches, the relevance of natural products persists. While they present both challenges and opportunities, ultimately, integrating natural product libraries and screening pipelines supports hit identification, lead optimization, and translational research.
Chemical diversity and biological relevance of natural product libraries
Natural product libraries are derived from plants, fungi, bacteria, marine organisms, and other biological sources. Unlike synthetic compound libraries, they reflect millions of years of evolutionary tuning, often providing an inherent ability to mediate biological interactions. Their bias toward biological activity increases the likelihood of functional interactions with targets, even in the absence of prior target knowledge.
Additionally, natural product libraries offer structurally complex scaffolds, diverse ring systems, and functional group richness, all of which are often absent in synthetic libraries.
These characteristics enable natural product libraries to cover a broad chemical space, resulting in high hit rates and positioning them as a key source of new drugs. However, several limitations exist, including:
- Variability in source material composition: Differences in organism genetics, environment, or growth conditions can alter metabolite profiles and chemical consistency.
- Supply constraints: Limited natural abundance or slow-growing sources can restrict the ability to isolate sufficient quantities for research and development.
- Challenges in purification and characterization: Complex mixtures require extensive fractionation and analytical workflows to isolate and identify active constituents.
- Batch-to-batch reproducibility issues: Variability in extraction conditions and biological material leads to inconsistent composition across preparations.
Despite these constraints, natural product libraries remain critical in drug discovery.
Natural product screening strategies
Natural product screening differs from conventional HTS primarily due to sample complexity and heterogeneity. Three major workflow stages are typically employed in natural product discovery: crude extract screening, fractionation, and screening of purified compounds (Table 1).
Table 1: Screening strategies used in natural product workflows.
Screening Strategy | Description | Advantages | Limitations |
Crude extract screening | Direct testing of unpurified, whole biological extracts | Captures synergistic biological effects, provides full chemical diversity of the source | Complex deconvolution process |
Fractionation | Pre-separated chemical fractions are tested | Improved hit resolution | Requires additional processing |
Pure compound investigation | Isolated natural products | Clear structure-activity relationships | Resource intensive |
Across these workflow stages, a variety of screening methodologies are applied to enable the identification, prioritization, and characterization of bioactive compounds. Methods for natural product screening include:
- Phenotypic screening: This approach assesses compound-induced changes in observable cellular or organismal phenotypes. It is widely used when mechanisms of action are unknown or complex.
- Target-based assays: These assays measure the direct interaction between compounds and defined biological targets, such as enzymes or receptors, to assess modulation of activity. They are applied when molecular targets are known or hypothesized.
- HTS: Enables rapid, large-scale testing of thousands of samples in parallel using robotic systems to identify bioactive hits. HTS is increasingly adapted for natural product libraries.
- Bioassay-guided fractionation: This method involves sequential separation of complex mixtures while repeatedly testing fractions to isolate and identify the specific active compound responsible for the observed bioactivity.
Prioritization of novel compounds in natural product screening
A distinguishing feature of natural product screening is the reliance on iterative fractionation and dereplication to rapidly exclude known compounds and prioritize novel bioactive compounds.
Dereplication strategies
Dereplication strategies are analytical workflows that combine spectroscopy techniques and database matching to rapidly identify known compounds.
Dereplication reduces redundancy by identifying known natural products early in the workflow.
Techniques include:
Improving Efficiency in Routine PFAS Analysis Using EPA Methods 533 and 1633A
In this webinar, explore a practical approach to PFAS analysis using EPA Methods 533 and 1633A, with application data illustrating low-level quantitation, accuracy and precision in quality control samples, chromatographic separation of challenging inView Webinar
- Liquid chromatography-tandem mass spectrometry (LC-MS)
- Nuclear magnetic resonance (NMR)-based spectral matching
- Database comparison (e.g., natural product repositories)
- Mass spectral fragmentation pattern analysis
These approaches streamline molecule discovery by focusing resources on uncharacterized entities.
Small-molecule discovery from natural product libraries
Natural product libraries remain one of the most productive sources of lead structures in small-molecule discovery. Over the last four decades, approximately one quarter of new drugs approved worldwide are derived from natural products—including antibiotics, anticancer agents, and immunosuppressants (Figure 1).
Figure 1: Therapeutic areas influenced by natural products. Credit: AI-generated image created using Microsoft Copilot (2026).
Key advantages of using natural product libraries in small-molecule discovery include:
- Novel scaffolds: Natural products offer unique ring systems and stereochemistry not commonly found in synthetic libraries.
- Mechanistic diversity: Target proteins, membranes, and signaling pathways vary, sometimes revealing unconventional opportunities for modulation.
- Allosteric modulation: Natural products often bind non-active sites, offering regulatory advantages.
- Multi-target activity: Particularly relevant in complex diseases such as cancer and neurodegeneration.
Integration of computational tools in natural product libraries
The integration of computational methods has significantly enhanced the efficiency of natural product screening workflows.
Accelerate your PROTACs drug discovery and development
This eBook shows how an integrated, end-to-end analytical approach helps labs generate reliable, regulatory-ready PROTAC data at every stage of development.View eBook
Key developments include:
- In silico dereplication: This facilitates prediction of known compounds prior to isolation.
- Machine learning models: Models are able to predict bioactivity from structural features.
- Molecular docking simulations: These can identify potential protein–ligand interactions ahead of experiments.
- Network pharmacology approaches: Researchers can map multi-target effects of natural compounds to predict desired and undesired activity.
These tools help bridge experimental and computational workflows, reducing redundancy and accelerating hit identification in natural product screening pipelines.
Natural product libraries vs synthetic and combinatorial libraries
A key consideration in modern drug discovery is how natural product libraries compare with synthetic and combinatorial approaches (Table 2).
Table 2: Comparison of natural product, synthetic, and combinatorial libraries.
| Library Type | Chemical diversity | Structural complexity | Hit rate in phenotypic screening | Key limitation |
| Natural product libraries | Very high | High | High | Supply and scalability |
| Synthetic libraries | Moderate | Moderate | Moderate | Limited structural novelty |
| Combinatorial libraries | Variable | Low–moderate | Variable | Overrepresentation of flat structures |
Natural product libraries are advantageous in early-stage discovery, particularly when biological targets are unknown. Synthetic libraries, in contrast, offer scalability and reproducibility but often lack the structural diversity needed to cover large areas of unexplored biological space.
Combinatorial libraries bridge some of these gaps but frequently underrepresent complex three-dimensional scaffolds characteristic of natural compounds.
Researchers can combine these approaches to leverage the structural diversity of natural products while maintaining the scalability and tunability of synthetic and combinatorial collections.
Translational relevance of natural product libraries in drug development
The translational value of natural product libraries extends beyond initial hit identification. These compounds often serve as starting points for various applications: drug development, biomarker identification, and elucidation of disease-relevant biological pathways.
Advancing Host Cell Protein Characterization With Proteomics
Drawing on real-world case studies from industry, attendees will learn practical approaches for achieving deeper proteome coverage, improved quantitative performance, and more robust HCP profiling across complex biopharmaceutical samples.View Webinar
With regard to drug development, natural scaffolds can be chemically modified to improve potency, solubility, and stability, and multiple FDA-approved drugs originate directly or indirectly from natural products.
Despite their promise, translation efforts face several challenges:
- Complex synthesis
- Intellectual property constraints
- Supply chain limitations for rare natural sources
- Regulatory complexity in defining composition and consistency
Nevertheless, advances in synthetic biology and metabolic engineering are improving scalability by enabling microbial production of bioactive natural products.
The enduring role of natural product libraries in drug discovery
Natural product libraries remain a uniquely powerful resource in drug discovery, combining structural complexity with biologically relevant activity profiles.
Their integration into natural product screening workflows enables efficient identification of bioactive compounds and accelerates drug discovery across diverse therapeutic and diagnostic areas.
While synthetic and combinatorial approaches have expanded accessible chemical space, natural products remain unmatched in their functional diversity. Advances in computational screening, dereplication technologies, and synthetic biology are enhancing their scalability and translational potential.
With a growing global disease burden and persistent unmet medical needs, natural product libraries are expected to maintain a central role in early-stage discovery to support the development of novel therapeutics.
This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
